FI104232B - Användning av hirudinderivat som trombininhibitorer - Google Patents
Användning av hirudinderivat som trombininhibitorer Download PDFInfo
- Publication number
- FI104232B FI104232B FI935707A FI935707A FI104232B FI 104232 B FI104232 B FI 104232B FI 935707 A FI935707 A FI 935707A FI 935707 A FI935707 A FI 935707A FI 104232 B FI104232 B FI 104232B
- Authority
- FI
- Finland
- Prior art keywords
- hirudin
- dextran
- hirudins
- thrombin
- thrombin inhibitors
- Prior art date
Links
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical class C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title claims description 52
- 229940122388 Thrombin inhibitor Drugs 0.000 title claims description 5
- 239000003868 thrombin inhibitor Substances 0.000 title claims description 5
- 102000007625 Hirudins Human genes 0.000 claims description 41
- 108010007267 Hirudins Proteins 0.000 claims description 41
- 229940006607 hirudin Drugs 0.000 claims description 36
- 229920002684 Sepharose Chemical group 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229920002307 Dextran Polymers 0.000 claims description 7
- 239000002202 Polyethylene glycol Chemical group 0.000 claims description 4
- 229920001223 polyethylene glycol Chemical group 0.000 claims description 4
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 150000002669 lysines Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- -1 Dextrane (MW 20 Chemical class 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VJZRBVVLWLEXBB-VROPFNGYSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[2-[(4-methylphenyl)sulfonylamino]acetyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1S(=O)(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCC1 VJZRBVVLWLEXBB-VROPFNGYSA-N 0.000 description 1
- OELQSSWXRGADDE-UHFFFAOYSA-N 2-methylprop-2-eneperoxoic acid Chemical compound CC(=C)C(=O)OO OELQSSWXRGADDE-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 101000993302 Hirudo medicinalis Hirudin variant-1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002885 Polygeline Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 108010018472 chromozym TH Proteins 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-M periodate Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229960004250 polygeline Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Claims (2)
1. Användning av hirudin som är bundet till dext-ran, Sepharose eller polyetylenglykol (MW 1 500 - 15 000 5 dt) som in vitro trombininhibitor.
2. Förfarande för att belägga ytan pä medicinska medel, kännetecknat av att de beläggs med hirudin som är bundet till dextran, Sepharose eller polyetylenglykol (MW 1 500 - 15 000 dt). • · · • · • · · • · · ··· · • · · * · V * o * · • · o « · t • · * • · « • · · • · · • · · • · · • · · « * « « « I (It t ·
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3819079 | 1988-06-04 | ||
| DE3819079A DE3819079A1 (de) | 1988-06-04 | 1988-06-04 | Hirudin-derivate mit verzoegerter wirkung |
| FI892686A FI98703C (sv) | 1988-06-04 | 1989-06-01 | Förfarande för framställning av ett hirudinderivat |
| FI892686 | 1989-06-01 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI935707L FI935707L (fi) | 1993-12-17 |
| FI935707A0 FI935707A0 (fi) | 1993-12-17 |
| FI104232B true FI104232B (sv) | 1999-12-15 |
| FI104232B1 FI104232B1 (sv) | 1999-12-15 |
Family
ID=25868824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI935707A FI104232B1 (sv) | 1988-06-04 | 1993-12-17 | Användning av hirudinderivat som trombininhibitorer |
Country Status (1)
| Country | Link |
|---|---|
| FI (1) | FI104232B1 (sv) |
-
1993
- 1993-12-17 FI FI935707A patent/FI104232B1/sv active
Also Published As
| Publication number | Publication date |
|---|---|
| FI935707L (fi) | 1993-12-17 |
| FI104232B1 (sv) | 1999-12-15 |
| FI935707A0 (fi) | 1993-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI98703C (sv) | Förfarande för framställning av ett hirudinderivat | |
| AU760580B2 (en) | Factor VIIa inhibitors | |
| US5256559A (en) | Methods and compositions for inhibiting platelet aggregation | |
| PL188132B1 (pl) | Związki, które specyficznie inhibitują aktywność czynnika Xa oraz zawierająca je kompozycja farmaceutyczna | |
| KR20170137929A (ko) | 효소 활성화 인자 XII(FXIIa)의 신규한 저해제 | |
| US5433940A (en) | Inhibitors of thrombin | |
| AU623882B2 (en) | Methods and compositions for inhibiting platelet aggregation | |
| RU2073685C1 (ru) | Полипептиды или их соли, фармацевтическая композиция, обладающая противовирусной активностью в отношении вируса иммунодефицита человека | |
| WO1999024075A2 (en) | Affinity markers for human serum albumin | |
| WO1990003391A1 (en) | Hirudin peptides | |
| JPH06293799A (ja) | ポリペプチド | |
| Kuyas et al. | Isolation of human fibrinogen and its derivatives by affinity chromatography on Gly-Pro-Arg-Pro-Lys-Fractogel | |
| Sidorova et al. | Peptide fragments and structural analogues of chemokine MCP-1: synthesis and effect on the MCP-1-induced migration of mononuclear cells | |
| Björk et al. | The structure around the thioester bond in bovine α2-macroglobulin: Possible implications for the conformational stability of the inhibitor on thioester cleavage | |
| US5262521A (en) | Isolated atrial peptide-degrading enzyme and novel compounds useful as inhibitors thereof | |
| JPH09503221A (ja) | 血液凝固のカスケードにおいて治療上活性である新規ペプチド誘導体、その製造方法、及びそれらを含有する医薬組成物 | |
| HK1006024B (en) | Hirudin derivatives with delayed action | |
| Nagase et al. | Amino acid sequence of a 32-residue region around the thiol ester site in duck ovostatin | |
| Fox et al. | IDENTIFICATION OF GLYCOPROTEIN Ib8 AS THE Mr= 24,000 PLATELET POLYPEPTIDE PHOSPHORYLATED BY AGENTS THAT ELEVATE CYCLIC AMP | |
| MXPA01002400A (en) | FACTOR VIIa INHIBITORS | |
| JPH04198194A (ja) | ポリペプチドおよびその用途 | |
| JP2011527991A (ja) | ポリペプチド系物質、その製造方法及び用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH Free format text: SANOFI-AVENTIS DEUTSCHLAND GMBH |